Table 1.

key characteristics and outcomes of enrolled CF patients diagnosed with SARS-CoV-2 infection.

Patient	First CFTR variant	Second CFTRvariant	Age atSARS-CoV-2 infection(years)	Symptoms	Microbiologicalstatus	Pre infectionFEV₁ (%)	Post infectionFEV₁ (%)	Pre infectionBMI ^a	Post infectionBMI ^a
1	2789+5G>A	1602delCT	54	Fever	Burkholderia gladioli	33	36	27.67	27.67
2	F508Del	CFTR Dele 2	14	None	MSSA	40	37	36.88	80.5
3	F508Del	N1303K	26	None	MSSA	53	53	25.51	25.21
4	E585X	Dele 22-24	10.5	Cough	MSSA	86	95	52.33	60.42
5	R347H	G542X	59	Myalgia, fever	MSSA	51	63	21.89	21.74
6	F508Del	A1006E	4.5	Cough, wheezing	MSSA	na^b	na^b	61.68	50.75
7	F508Del	(TG)12T5	10	None	MSSA	126	98	84.14	76.53
8	F508Del	G542X	30	None	Stenotrophomonas maltophilia.	72	76	19.72	20.26
9	G178R	L1065P	40	Cough, fever myalgia	MSSA	87	92	26.96	26.6
10	F508Del	G542X	3 months	None	Normal flora	na^b	na^b	0.65^c	1.24^c
11	F508Del	D192G	57.5	Cough	Pseudomonas aeruginosa	44	42	19.14	19.53
12	F508Del	F508Del	31	None	MSSA	61	65	20.27	20.13
13	F508Del	L1065P	13.8	None	MSSA	72	77	65.09	52.79

Abbreviations: SARS-CoV-2: severe acute respiratory syndrome coronavirus-2; MSSA: Methicillin-susceptible Staphylococcus aureus; FEV_1: predicted forced expiratory volume in one second; BMI: body mass index; CFTR: cystic fibrosis transmembrane conductance regulator; na: not available

we report BMI data in patients younger than 20 years as BMI centile

children aged < 6 years

we refer to weight/length centile given the age of the child